[Comment] The patient pursuit of safe treatment options for tuberculosis

The recent progress in the development, evaluation, and global implementation of all oral, shorter, efficacious regimens ushered in a new era of optimism for the treatment of drug-resistant tuberculosis.1 This has largely been made possible through the discovery of novel chemical entities, including a diarylquinoline (bedaquiline) and nitroimidazoles (pretomanid and delamanid), and the repurposing of an oxazolidinone (linezolid), which was previously used for the treatment of drug-resistant Gram-positive infections.